Although treatment responses to anti-PD-1 or anti-PD-L1 antibody therapies are associated with the expression of PD-L1 protein in tumor tissues, approximately 10–40% of PD-L1-negative patients also respond to anti-PD-1 or anti-PD-L1 therapies (18, 19). This evidence concerns the gene CD274 and neoplasm.